Pregled bibliografske jedinice broj: 1166007
The Outcome of Hemolytic Disease of the Fetus and Newborn Caused by Anti-Rh17 Antibody: Analysis of Three Cases and Review of the Literature
The Outcome of Hemolytic Disease of the Fetus and Newborn Caused by Anti-Rh17 Antibody: Analysis of Three Cases and Review of the Literature // Transfusion medicine and hemotherapy, 43 (2020), 3; 264-271 doi:10.1159/000503012 (međunarodna recenzija, pregledni rad, stručni)
CROSBI ID: 1166007 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The Outcome of Hemolytic Disease of the Fetus
and Newborn Caused by Anti-Rh17 Antibody:
Analysis of Three Cases and Review of the
Literature
Autori
Dajak, Slavica ; Ipavec, Nina ; Ćuk, Mia ; Golubić Ćepulić, Branka ; Mratinović Mikulandra, Jela ; Milardović, Josipa ; Stefanović, Vedran
Izvornik
Transfusion medicine and hemotherapy (1660-3796) 43
(2020), 3;
264-271
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni
Ključne riječi
Anti-Rh17 · Hemolytic disease of the fetus and newborn · D-- phenotype
Sažetak
To high-frequency antigens that may cause severe hemolytic disease of the fetus and newborn (HDFN). Despite the rarity of HDFN caused by Anti-Rh17, this antibody was reported in many different populations. Emergency transfusions, especially exchange transfusions, present a huge problem if no compatible RBCs of phenotype D-- are available. Methods: Here we report obstetrical histories of three women and describe their pregnancies complicated by anti-Rh17 antibodies. We summarized published cases of pregnancies complicated by anti-Rh17 and reviewed transfusion treatment and outcomes. Additionally, a simplified flowchart for the management of such pregnancies is proposed. Results: Four pregnancies were affected by severe HDFN, and three of them ended with perinatal death. In the fourth case, the baby was born hydropic and icteric and the condition was rapidly deteriorating. Emergency exchange transfusion was performed with incompatible O-negative RBC units in AB- negative plasma. The baby was discharged on the 14th day in good health. In the available literature, 15 women and 22 pregnancies were reported, 20 of them developed severe HDFN. According to the data, intrauterine transfusion for treatment of HDFN was the most common form of treatment with the donation of the mother’s blood. Different options for exchange transfusion were described, including incompatible RBCs. Conclusion: In more than 90% of described pregnancies of HDFN caused by anti-Rh17 antibody, transfusion treatment was required. Therefore, RBC from D-- phenotype has to be available. According to published data, in emergent circumstances when maternal and blood from donor with phenotype D-- is not available, incompatible exchange transfusion is a better choice than delaying transfusion when it is necessary. It is of essential importance that pregnancies with high risk of HDFN due to anti-Rh17 are managed by a multidisciplinary team (transfusion medicine specialist, obstetrician, neonatologist) in a highly specialized tertiary institution.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Branka Golubić Ćepulić
(autor)
Jela Mratinović-Mikulandra
(autor)
Slavica Dajak
(autor)
Vedran Stefanović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus